Antibody Therapeutics for Life

Press Release

PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC
  • Written by PharmAbcine
  • Written date 2020-08-20 16:14:54
  • Inquire 154

PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC








List





Prev PharmAbcine to Present Preclinical Data of Blood Vessel Stabilizing PMC-402 at 2...
Next PharmAbcine announces the execution of a Material Cooperative Research and Devel...